ATYR9123

ATYR9123 is an investigational **anti-neuropilin-2 therapeutic antibody** from aTyr Pharma being developed in oncology. Public company materials identify it as part of aTyr's NRP2 antibody program and distinguish it from efzofitimod and ATYR2810. Although detailed molecular format, epitope, and clinical pharmacology have not been broadly disclosed in accessible primary-source public materials, the program rationale is to inhibit **neuropilin-2 signaling**, a pathway implicated in tumor biology and immunosuppressive mechanisms in the tumor microenvironment. Available public evidence indicates ATYR9123 remained a preclinical or early development code name/program asset, with no clearly documented approved indication or marketed product status.